Inspire Will Market AzaSite With 98-Rep Sales Force
Company announces agreement with InSite Vision to license bacterial conjunctivitis treatment pending at FDA with a late April user fee date.
Company announces agreement with InSite Vision to license bacterial conjunctivitis treatment pending at FDA with a late April user fee date.